Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone

Schizophrenia Bulletin

Volumn 33, Issue 6, 2007, Pages 1379-1387

  Olfson, Mark ^a   Marcus, Steven C ^b   Ascher Svanum, Haya ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Community treatment; Depot antipsychotic medications; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYPNOTIC AGENT; LONG ACTING DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; DRUG USE; FEMALE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL PATIENT; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; FLUPHENAZINE; HALOPERIDOL; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 35648972201     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm033     Document Type: Article

References (49)

1. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64(suppl 16)14-17.
2. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004;55:997-1005.
3. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40:630-639.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Available at: http://www.psych.org/psych_pract/ treatg/pg/Practice%20Guidelines 8904/Schizophrenia2e.pdf Accessed June 17, 2006.
5. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30:193-217.
6. Kane JM, Leucht S, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(suppl 12):5-100.
7. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53:426-433.
8. Rothbard AB, Kuno E, Roley K. Trends in the rate and type of antipsychotic medications prescribe to persons with schizophrenia. Schizophr Bull. 2003;29:531-540.
9. West JC, Wilk J, Olfson M, et al. Patterns and quality of treatment of patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56:283-291.
10. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharm Bull. 1996;32:321-326.
11. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58:482-488.
12. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65:1377-1388.
13. Arnold LM, Strakowski SM, Schwiers ML, et al. Sex ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66:169-175.
14. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharamcodynamics. J Clin Psychiatry. 2003;64(suppl 16):18-23.
15. Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002;53:25-30.
16. Aravagiri M, Marder SR, Van Putten T, Marshall BD. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J Chromatogr Biomed Appl. 1994;656:373-381.
17. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10:2219-2229.
18. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Commun Psychiatry. 1992;433:69-71.
19. Shireman TI, Svarstad BL, Sweeney JK. Validity of claims for long-acting injectable medications. J Pharmacoepidemiol. 1999;7:41-55.
20. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
21. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk or rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.
22. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491.
23. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
24. Lacro JP, Dunn LB, Dolder CR, Leckban SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
25. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30:255-264.
26. Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65:1076-1083.
27. Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mlbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand. 1991;84:13-21.
28. Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia: a long-term double-blind cross-over comparison. Acta Psychiatr Scand. 1986;74:255-262.
29. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159:554-560.
30. Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry. 1999;33:896-901.
31. Bergen J, Hunt G, Armitage P, Bashir M. Six-month outcome following a relapse of schizophrenia. Aust N Z J Psychiatry. 1998;32:815-822.
32. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51:216-222.
33. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
34. Casey DE, Hansen TE. Excessive morbidity and mortality in schizophrenia. In: Meyer JM, Nasrallah HA, eds. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Publishing; 2003.
35. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
36. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J. 2002;325:243-247.
37. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
38. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-184.
39. Novick D, Bousono M, Suarez D, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:972-982.
40. Whitehead C, Moss S, Cardino A, Lewis G. Antidepressant for people with both schizophrenia and depression. Cochrane Database Syst Rev. Issue 2 CD002305.
41. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev. Issue 3 CD001258.
42. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone inpatients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182-192.
43. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49:158-167.
44. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N E J Med. 2005;353:1209-1223.
45. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry. 2005;66:1016-1020.
46. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
47. Kwon A, Bungay KM, Pei U, et al. Antidepressant use: concordance between self-report and claims records. Med Care. 2003;41:368-374.
48. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248-1257.
49. Breekveldt-Postma NS, Schillevoort I, Nolen WA, Veraart CPWM, Herings RMC. Selective prescribing of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2005;14:25-30.